REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $27.50.

A number of brokerages recently issued reports on RGNX. Robert W. Baird set a $27.00 price target on REGENXBIO in a report on Tuesday, February 10th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Stifel Nicolaus lifted their target price on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Chardan Capital dropped their price target on REGENXBIO from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th.

REGENXBIO Price Performance

RGNX stock opened at $8.38 on Wednesday. The company has a market capitalization of $432.49 million, a PE ratio of -2.23 and a beta of 1.08. REGENXBIO has a 12 month low of $5.03 and a 12 month high of $16.19. The firm’s 50-day moving average is $9.53 and its 200 day moving average is $11.37.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.29). The company had revenue of $30.34 million during the quarter, compared to analysts’ expectations of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. Sell-side analysts forecast that REGENXBIO will post -4.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other REGENXBIO news, insider Steve Pakola sold 5,124 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $10.35, for a total transaction of $53,033.40. Following the transaction, the insider directly owned 247,926 shares in the company, valued at $2,566,034.10. This represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently modified their holdings of RGNX. Jones Financial Companies Lllp boosted its stake in shares of REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,270 shares in the last quarter. Profund Advisors LLC increased its holdings in REGENXBIO by 11.8% during the third quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 1,523 shares during the period. Deutsche Bank AG raised its stake in REGENXBIO by 0.8% in the fourth quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock worth $2,773,000 after buying an additional 1,527 shares in the last quarter. Captrust Financial Advisors lifted its holdings in REGENXBIO by 13.2% during the fourth quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock worth $219,000 after buying an additional 1,781 shares during the period. Finally, Pale Fire Capital SE lifted its holdings in REGENXBIO by 7.7% during the second quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock worth $229,000 after buying an additional 2,000 shares during the period. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.